(Q48019865)

7 February 2018

title

Treatment of chronic diabetic lower leg ulcers with activated protein C: a randomised placebo-controlled, double-blind pilot clinical trial (English)

1 reference

7 February 2018

1 reference

1 reference

Kaley Whitmont

1

1 reference

7 February 2018

Kelly J McKelvey

2

1 reference

7 February 2018

Gregory Fulcher

3

1 reference

7 February 2018

Ian Reid

4

1 reference

7 February 2018

Lyn March

5

1 reference

7 February 2018

Meilang Xue

6

1 reference

7 February 2018

Alan Cooper

7

1 reference

7 February 2018

Christopher J Jackson

8

1 reference

7 February 2018

publication date

15 July 2013

1 reference

7 February 2018

International Wound Journal

published in

1 reference

7 February 2018

volume

12

1 reference

7 February 2018

issue

4

1 reference

7 February 2018

page(s)

422-427

1 reference

7 February 2018

Treatment of nonhealing diabetic foot ulcers with a platelet-derived growth factor gene-activated matrix (GAM501): results of a phase 1/2 trial

cites work

1 reference

Plastic surgical perspectives on vascular endothelial growth factor as gene therapy for angiogenesis

21 January 2018

1 reference

Phase I trial on the safety of topical rhVEGF on chronic neuropathic diabetic foot ulcers.

21 January 2018

1 reference

The role of vascular endothelial growth factor in wound healing

21 January 2018

1 reference

Recombinant hepatocyte growth factor accelerates cutaneous wound healing in a diabetic mouse model

21 January 2018

1 reference

Human epidermal growth factor enhances healing of diabetic foot ulcers.

21 January 2018

1 reference

Recombinant human epidermal growth factor (EGF) to enhance healing for diabetic foot ulcers.

21 January 2018

1 reference

Efficacy and safety of a topical gel formulation of recombinant human platelet-derived growth factor-BB (becaplermin) in patients with chronic neuropathic diabetic ulcers. A phase III randomized placebo-controlled double-blind study

21 January 2018

1 reference

Treatment of chronic leg ulcers with topical activated protein C.

21 January 2018

1 reference

Activated protein C stimulates proliferation, migration and wound closure, inhibits apoptosis and upregulates MMP-2 activity in cultured human keratinocytes.

21 January 2018

1 reference

Protease activated receptor-2 mediates activated protein C-induced cutaneous wound healing via inhibition of p38

21 January 2018

1 reference

Activated protein C prevents inflammation yet stimulates angiogenesis to promote cutaneous wound healing.

21 January 2018

1 reference

Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus

21 January 2018

1 reference

Randomized prospective double-blind trial in healing chronic diabetic foot ulcers. CT-102 activated platelet supernatant, topical versus placebo

21 January 2018

1 reference

Gene expression profile of antithrombotic protein c defines new mechanisms modulating inflammation and apoptosis

21 January 2018

1 reference

Activated protein C utilizes the angiopoietin/Tie2 axis to promote endothelial barrier function.

21 January 2018

1 reference

Efficacy and safety of recombinant human activated protein C for severe sepsis

21 January 2018

1 reference

Quality of life in patients with diabetic foot ulcers: validation of the Cardiff Wound Impact Schedule in a Canadian population

21 January 2018

1 reference

Cardiff Wound Impact Schedule: the development of a condition-specific questionnaire to assess health-related quality of life in patients with chronic wounds of the lower limb.

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1111/IWJ.12125

1 reference

7 February 2018

1 reference

7 February 2018